Novavax lost more than $600 million last year
Author of the article:
MONTREAL — An American company that signed a deal with the federal government to produce COVID-19 vaccines in Montreal has warned investors it could go out of business within the year.
Subscribe now to read the latest news in your city and across Canada.
Subscribe now to read the latest news in your city and across Canada.
Create an account or sign in to continue with your reading experience.
Don’t have an account? Create Account
Executives at Maryland-based Novavax Inc. told investors on a conference call Tuesday that there is significant uncertainty surrounding the company’s ability to continue funding operations as the market for COVID-19 vaccines changes.
Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.
A welcome email is on its way. If you don’t see it, please check your junk folder.
The next issue of Financial Post Top Stories will soon be in your inbox.
We encountered an issue signing you up. Please try again
“While our current business plan and cash flow forecast estimate that we have sufficient capital available to fund our operations for the next 12 months, we recognize that this plan is subject to significant uncertainty,” Jim Kelly, Novavax’s chief financial officer, said on the call.
He said the company, which lost more than $600 million last year, doesn’t expect to sell any new vaccine during the first three months of 2023 and there are fears that funding from the United States government could be cut.
The company, which has more than $1.3 billion in cash on hand, is counting on its ability to develop and sell an updated COVID-19 vaccine next fall and is cutting costs, Kelly told investors.
In February 2021, the federal government announced a deal with Novavax to begin producing its vaccine at a National Research Council (NRC) facility in Montreal.
At the time, Industry Minister François-Philippe Champagne said the facility — which has the potential to produce around two million doses of vaccine a month — would be in a position to begin production at the end of 2021.
However, on an NRC website last updated in December, the federal science and technology agency said it is still working on the “technology transfer” required to produce the vaccine.
In an email Wednesday evening, Novavax said it remains committed to making its vaccine in Canada.
“Novavax continues to make progress towards establishing local manufacturing capabilities in partnership with NRC/(Biologics Manufacturing Centre), with manufacturing of process performance qualification batches expected to begin in early 2023,” the company said.
Laurie Bouchard, a spokeswoman for Champagne, said in an email that “at this time, there are no expected changes to the partnership between Novavax and the BMC.”
The company is currently the NRC’s only client at the Montreal biomanufacturing centre, which was completed in 2021 and is intended to produce biopharmaceuticals such as vaccines.
“We’re continuing to explore options with potential collaborators on producing vaccines and other biologics at the facility on its second production line,” Christine Jodoin, the vice-president of strategic initiatives at the NRC, wrote in an email.
Canada has struggled to ramp up COVID-19 vaccine production. A deal with Chinese company CanSino Biologics — which could have seen the company’s vaccine manufactured at the Montreal facility — fell apart in the summer of 2020.
Mitsubishi Chemical announced early last month that another company planning the commercial manufacture of COVID-19 vaccines in Canada, Quebec-based Medicago Inc., would be shut down.
However, in August, vaccine giant Moderna announced it would build a new manufacturing facility in the Montreal suburb of Laval.
Bouchard said the government’s approach to acquiring COVID-19 vaccines ensured Canadians had access to vaccines quickly and reversed 40 years of decline in Canada’s biomanufacturing sector.
“So far, we have invested $1.8 billion towards 33 projects across the country and we continue to invest in the researchers, talent and innovation that will keep strengthening the Canadian life sciences ecosystem,” she wrote.
Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.
There is not sufficient evidence to recommend more than one COVID-19 booster shot a year for older people and those with weakened immune systems, an expert advisory group to the U.S. Centers for Disease Control and Prevention (CDC) said on Friday.
Novavax Inc’s shares plunged 28% in U.S. early trading on Wednesday, a day after the COVID-19 vaccine maker raised doubts about its ability to remain in business.
Novavax Inc’s shares plunged to a three-year low on Wednesday, a day after the COVID-19 vaccine maker raised doubts about its ability to remain in business.
Novavax Inc’s shares plunged to a three-year low on Wednesday, a day after the COVID-19 vaccine maker raised doubts about its ability to remain in business.
TORONTO — TD Bank Group’s US$13.4-billion takeover of First Horizon is in doubt as it looks to further extend the closing date of the deal.
365 Bloor Street East, Toronto, Ontario, M4W 3L4
© 2023 Financial Post, a division of Postmedia Network Inc. All rights reserved. Unauthorized distribution, transmission or republication strictly prohibited.
This website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Service and Privacy Policy.